FDA — authorised 10 July 1963
- Application: NDA014103
- Marketing authorisation holder: LILLY
- Local brand name: ONCOVIN
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Oncovin in United States
FDA authorised Oncovin on 10 July 1963
Marketing authorisations
FDA — authorised 17 July 1987
- Application: ANDA071426
- Marketing authorisation holder: TEVA PARENTERAL
- Local brand name: VINCASAR PFS
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 19 April 1988
- Application: ANDA071484
- Marketing authorisation holder: HOSPIRA
- Local brand name: VINCRISTINE SULFATE PFS
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 1 September 1999
- Application: ANDA075493
- Marketing authorisation holder: TEVA PHARMS USA
- Local brand name: VINCRISTINE SULFATE PFS
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 20 December 2002
- Application: ANDA076296
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: VINCRISTINE SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 28 October 2003
- Application: ANDA076401
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: VINCRISTINE SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 9 August 2012
- Application: NDA202497
- Marketing authorisation holder: ACROTECH
- Local brand name: MARQIBO KIT
- Indication: INJECTABLE, LIPOSOMAL — INTRAVENOUS
- Status: approved
FDA
- Application: ANDA070777
- Marketing authorisation holder: QUAD PHARMS
- Local brand name: VINCRISTINE SULFATE
- Indication: Injectable — Injection
- Status: approved
FDA
- Application: ANDA070778
- Marketing authorisation holder: QUAD PHARMS
- Local brand name: VINCRISTINE SULFATE
- Indication: Injectable — Injection
- Status: approved
FDA
- Application: ANDA071937
- Marketing authorisation holder: QUAD PHARMS
- Local brand name: VINCRISTINE SULFATE
- Indication: Injectable — Injection
- Status: approved
FDA
- Application: ANDA070411
- Marketing authorisation holder: ABRAXIS PHARM
- Local brand name: VINCRISTINE SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA071559
- Marketing authorisation holder: HOSPIRA
- Local brand name: VINCRISTINE SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA071560
- Marketing authorisation holder: HOSPIRA
- Local brand name: VINCRISTINE SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA071561
- Marketing authorisation holder: HOSPIRA
- Local brand name: VINCRISTINE SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070873
- Marketing authorisation holder: ABIC
- Local brand name: VINCRISTINE SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
Oncovin in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Oncovin approved in United States?
Yes. FDA authorised it on 10 July 1963; FDA authorised it on 17 July 1987; FDA authorised it on 19 April 1988.
Who is the marketing authorisation holder for Oncovin in United States?
LILLY holds the US marketing authorisation.